We are live on ! Find out more
ZVRA icon

Zevra Therapeutics
ZVRA

6 hedge funds and large institutions have $360K invested in Zevra Therapeutics in 2020 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

79% less funds holding

Funds holding: 29 → 6 (-23)

82% less capital invested

Capital invested by funds: $1.97M → $360K (-$1.61M)

96% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 24

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
6
Holders Change
-23
Holders Change %
-79.31%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
24
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$29.3K
2
AWA
Arete Wealth Advisors
Illinois
+$17.8K

Top Sellers

Rank Fund Capital Flow
1
DA
DSC Advisors
Illinois
-$922K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$346K
3
Creative Planning
Creative Planning
Kansas
-$101K
4
DM
Deerfield Management
New York
-$94K
5
RFN
RDA Financial Network
Iowa
-$58K

ZVRA Hedge Fund Activity: Q2 2020 in Review

6 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2020, worth a combined $360K — down 82% from $1.97M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of ZVRA and 1 opened new positions — a net loss of 23 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Acadian Asset Management, opening a new position worth an estimated $29.3K. The largest seller was DSC Advisors, exiting entirely with an estimated $922K sold.

  • 6 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2020, down from 29 in Q1 2020.
  • Funds reported $360K of Zevra Therapeutics stock for Q2 2020, down 82% quarter-over-quarter.
  • 1 fund opened new Zevra Therapeutics positions in Q2 2020 and 24 closed out, a net change of -23 holders.
  • The largest Zevra Therapeutics buyer in Q2 2020 was Acadian Asset Management, an estimated $29.3K added.
  • The largest Zevra Therapeutics seller in Q2 2020 was DSC Advisors, an estimated $922K sold.

Based on aggregated 13F filings for Q2 2020.